About the Recombinant Human Erythropoietin (rhEPO) Market in China
Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein responsible for producing erythrocytes in the body. In the fetal stage, this protein is produced in the liver; it is secreted by the kidneys in adulthood. During anemic conditions, the body produces an excess of EPO, maintaining the normal levels of red blood cells (RBC). When the endogenous production of EPO is disturbed because of diseases or the use of medications, the normal RBC levels can be maintained by an external supply of EPO-stimulating agents (ESAs). These agents are similar to the natural EPO in structure and function and are administered as injections. They can be produced by recombinant DNA technology and are used to treat anemia due to kidney diseases, cancer, HIV, injuries, or neural diseases.
Technavio’s analysts forecast the recombinant human erythropoietin (rhEPO) market in China to grow at a CAGR of 16.89% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the recombinant human erythropoietin (rhEPO) market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and biosimilars used for the treatment of anemia due to renal diseases, cancer chemotherapy, antiretroviral therapy, and wounds and neural diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.
The market is divided into the following segments based on application of rhEPO:
Technavio Announces the Publication of its Research Report – Recombinant Human Erythropoietin (rhEPO) Market in China 2016-2020
Technavio recognizes the following companies as the key players in the recombinant human erythropoietin (rhEPO) market in China: 3S Bio, Shanghai Chemo, Chengdu Di’ao, NCPC Genetech, Kyowa Hakko Kirin, and Shandong Kexing.
Other Prominent Vendors in the market are: Ahua Pharmaceutical, Biosidus, Dragon Pharma, Huaxin High Biotechnology, Kehua Bio-Engineering, LG Life Sciences, Shenzhen Sai Bao Er Bio-Pharmaceutical, Sihuan, Shenyang Sunshine Pharmaceutical, Uni-Bio Science Group, and Wanbang Biochemical Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “A major trend which will boost market growth is the exploitation of novel therapeutic methods. The use of EPO has expanded to therapeutic areas other than for the treatment of anemia. For instance, recombinant EPO therapy is used to treat cardio-renal anemia syndrome. Use of EPO has shown an improvement in left and right ventricular systolic function in such patients with the reduction in cardiac remodeling, brain natriuretic peptide (BNP) levels, and hospitalization rate. Apart from this, with the discovery of EPO receptors in non-erythroid tissues, EPO has been investigated as a novel therapeutic agent in diseases and therapeutic conditions, including spinal cord injury, depression, diabetes, and as an immunomodulating agent.”
According to the report, a key growth driver is the increase in CKD and dialysis patient population. An increase in the anemic population is expected to boost the market growth as EPO drugs are used as a treatment option for anemia. Anemia can be caused due to a number of diseases such as kidney disease, cancer, and HIV. In individuals with CKD, anemia develops due to the dysfunction of the kidneys. In this condition, the levels of EPO are low, which results in the development of anemia. Also, deficiency of iron, vitamin B12, and folic acid, which are essential for forming hemoglobin by RBCs, can result in anemia. The condition is aggravated in individuals undergoing dialysis; 80% of the individuals on dialysis are on EPO therapy to treat anemia
Further, the report states that one challenge that could restrict market growth is the complex manufacturing process. Unlike small molecule drugs, biologics are prepared from living organisms. Hence, the production process involved is complicated and time-consuming.
3S Bio, Shanghai Chemo, Chengdu Di’ao, NCPC Genetech, Kyowa Hakko Kirin, Shandong Kexing, Ahua Pharmaceutical, Biosidus, Dragon Pharma, Huaxin High Biotechnology, Kehua Bio-Engineering, LG Life Sciences, Shenzhen Sai Bao Er Bio-Pharmaceutical, Sihuan, Shenyang Sunshine Pharmaceutical, Uni-Bio Science Group, Wanbang Biochemical Pharmaceuticals.